HighTide Therapeutics (HKSE:02511) Earnings per Share (Diluted) : HK$-2.00 (TTM As of Dec. 2023)

View and export this data going back to 2023. Start your Free Trial

What is HighTide Therapeutics Earnings per Share (Diluted)?

HighTide Therapeutics's Earnings per Share (Diluted) for the six months ended in Dec. 2023 was HK$-0.83. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-2.00.

HighTide Therapeutics's EPS (Basic) for the six months ended in Dec. 2023 was HK$-0.83. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-2.00.

HighTide Therapeutics's EPS without NRI for the six months ended in Dec. 2023 was HK$-0.84. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-2.03.

HighTide Therapeutics Earnings per Share (Diluted) Historical Data

The historical data trend for HighTide Therapeutics's Earnings per Share (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

HighTide Therapeutics Earnings per Share (Diluted) Chart

HighTide Therapeutics Annual Data

Trend

Dec21

Dec22

Dec23

Earnings per Share (Diluted)

-0.53

-0.84

-3.96

HighTide Therapeutics Semi-Annual Data
	Dec21	Jun22	Dec22	Jun23	Dec23
Earnings per Share (Diluted)	-	-0.17	-0.25	-1.17	-0.83

Competitive Comparison of HighTide Therapeutics's Earnings per Share (Diluted)

For the Biotechnology subindustry, HighTide Therapeutics's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

HighTide Therapeutics's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, HighTide Therapeutics's PE Ratio distribution charts can be found below:

* The bar in red indicates where HighTide Therapeutics's PE Ratio falls into.

HighTide Therapeutics Earnings per Share (Diluted) Calculation

Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.

HighTide Therapeutics's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2023 is calculated as

Diluted Earnings Per Share (A: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Diluted Average)
	=	(-1027.393	-	0)	/	259.689
	=	-3.96

HighTide Therapeutics's Earnings Per Share (Diluted) for the quarter that ended in Dec. 2023 is calculated as

Diluted Earnings Per Share (Q: Dec. 2023 )	=	(Net Income	-	Preferred Dividends	/	Shares Outstanding (Diluted Average)
	=	(-426.095	-	0)	/	514.771
	=	-0.83

Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-2.00

Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.

HighTide Therapeutics (HKSE:02511) Earnings per Share (Diluted) Explanation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

HighTide Therapeutics Earnings per Share (Diluted) Related Terms

Thank you for viewing the detailed overview of HighTide Therapeutics's Earnings per Share (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.

HighTide Therapeutics (HKSE:02511) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » HighTide Therapeutics Inc (HKSE:02511) » Definitions » Earnings per Share (Diluted)

Comparable Companies

Traded in Other Exchanges

N/A

Address

Ganli Second Road, 18B-102, Zhonghaixin Innovation Industry City, Jihua Neighborhood, Longgang District, Guangdong, Shenzhen, CHN, 518112

Website

https://www.hightidetx.com

HighTide Therapeutics Inc is a biopharmaceutical company specializing in the discovery, development and commercialization of multifunctional, multi-targeted therapies for the treatment of metabolic and digestive diseases. The company has developed a product pipeline of five product candidates in-house, covering nine indications in metabolic and digestive diseases among which, five are at clinical-stage. The Core Product, HTD1801 (berberine ursodeoxycholate), a new molecular entity, is a gut-liver anti-inflammatory metabolic modulator which targets multiple pathways pivotal to metabolic regulation, including those associated with metabolic and digestive diseases.

Executives

Ma Lixiong	2101 Beneficial owner
Liu Liping	2101 Beneficial owner
Li Li	2201 Interest of corporation controlled by you
The Core Trust Company Limited
Shan Miao	2201 Interest of corporation controlled by you
Medi Prosperity Capital Inc.	2201 Interest of corporation controlled by you
Hepalink Healthcare Partners I L.p	2201 Interest of corporation controlled by you
Hepalink Biotechnology Ii Limited	2101 Beneficial owner
Hepalink (hong Kong) Limited	2201 Interest of corporation controlled by you
Shenzhen Hepalink Pharmaceutical Group Co., Ltd.	2501 Other
Wisdom Spring Group Limited
Tct (bvi) Limited
Baiyi Capital Limited	2101 Beneficial owner
Lai Hoi Man	2201 Interest of corporation controlled by you
Hongtu Capital Limited	2101 Beneficial owner

HighTide Therapeutics (HKSE:02511) Headlines

No Headlines